Dengue virus-reactive CD8<sup>+</sup> T cells mediate cross-protection against subsequent Zika virus challenge.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29129917.
- Also identified by DOI 10.1038/s41467-017-01669-z and PMC identifier 5682281.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Zika virus (ZIKV) and dengue virus (DENV) are antigenically related flaviviruses that share cross-reactivity in antibody and T cell responses, and co-circulate in increasing numbers of countries. Whether pre-existing DENV immunity can cross-protect or enhance ZIKV infection during sequential infection of the same host is unknown. Here, we show that DENV-immune Ifnar1 <sup>-/-</sup> or wild-type C57BL/6 mice infected with ZIKV have cross-reactive immunity to subsequent ZIKV infection and pathogenesis. Adoptive transfer and cell depletion studies demonstrate that DENV-immune CD8<sup>+</sup> T cells predominantly mediate cross-protective responses to ZIKV. In contrast, passive transfer studies suggest that DENV-immune serum does not protect against ZIKV infection. Thus, CD8<sup>+</sup> T cell immunity generated during primary DENV infection can confer protection against secondary ZIKV infection in mice. Further optimization of current DENV vaccines for T cell responses might confer cross-protection and prevent antibody-mediated enhancement of ZIKV infection.
Medical subject headings
- Adoptive Transfer
- CD8-Positive T-Lymphocytes
- Cross Protection
- Dengue Virus
- Zika Virus
- Zika Virus Infection